Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research - Supplemental New Drug Application for ARISTADA Two-Month Dose Under Review by FDA With Action Expected by June 5, 2017 - DUBLIN--(BUSINESS WIRE)--Mar. 20, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16International Congress on Schizophrenia Research (ICOSR) in San Diego, March 24-28, 2017. This will be the company's first presentation of pharmacokinetic (PK) data on the investigational...
↧